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concentrations were determined in paired blood and pericardial ﬂuid
samples taken once only at various time points in 16 patients and,
2) an intensive phase, during which intensive pharmacokinetic blood
and pericardial ﬂuid sampling were performed over a 24-hour period
in 11 additional patients. All participants received a standard ﬁxed-
dose-combination daily TB drug regimen, including rifampicin
(600mg), isoniazid (300mg), pyrazinamide (1600mg) and ethambutol
(1100mg). Penetration of rifampicin into pericardialﬂuidwas poor; the
ratio of rifampicin concentration in pericardial ﬂuid to paired blood con-median peak concentration in pericardial ﬂuid (performed in the inten-
Tuberculosis (TB) continues to be a major global health issue, with
the World Health Organization (WHO) reporting 9 million new TB
cases worldwide in 2013 (WHO, 2014). Since its endorsement by the
WHO in 1991, a combination of rifampicin, isoniazid, pyrazinamide
and ethambutol or streptomycin during the ﬁrst 2 months of treatment
has remained part of the standard ﬁrst-line TB treatment regimen
globally (WHO, 1991). These guidelines are based on historic trials
that assessed outcome during pulmonary TB treatment (Fox et al.,
1999). TB drug regimens used for extra-pulmonary TB, including
frequently fatal forms such as TB pericarditis and TB meningitis
(TBM), follow the same principles but not guided by trials that assessed
patient outcome. Inadequate TB drug exposure (as measured by
pharmacokinetic/pharmacodynamic [PK/PD] parameters in blood) is
associated with a poor clinical response, treatment failure and acquisi-
tion of drug resistance in pulmonary TB patients (Pasipanodya and
Gumbo, 2011). It is intuitive to assume that reduced drug exposure in
tissues due to inadequate drug penetration into extra-pulmonary
disease sites may enhance these detrimental effects.
In this issue of EBioMedicine, Shenje and colleagues present ﬁndings
of the ﬁrst study to determine TB drug concentrations in pericardial
ﬂuid of adults with pericardial TB (Shenje et al., 2015). The study was
divided into two phases: 1) a pilot study, during which rifampicinom.2015.09.025.
niversity of Cape Town, South
. This is an open access article undercentrationwas 0.19±0.33 (mean±SD) in the pilot study. Non-protein
bound rifampicin concentration (indicating active rifampicin) in
pericardial ﬂuid was extremely low (b1 mg/L) in all patients, and the
sive phase) was lower than themedianminimum inhibitory concentra-
tion (MIC) determined for TB strains collected previously from the same
setting. Previous studies in TBM similarly showed that rifampicin at
doses of 10 mg/kg/day seldom reaches cerebrospinal ﬂuid (CSF)
concentrations exceeding the MIC (Donald, 2010).
Shenje and colleagues (Shenje et al., 2015) further report poor
ethambutol penetration into pericardial ﬂuid; both 0–24 hour area
under the concentration–time curve (AUC0–24 h) and peak concentra-
tions (Cmax) were signiﬁcantly lower in pericardial ﬂuid compared to
plasma, resulting in ethambutol concentrations also falling below the
typical MIC. Pyrazinamide concentrations in pericardial ﬂuid were
similar to that in plasma. However, pyrazinamide is only active under
acidic conditions and after adjusting theMIC according to themeasured
pH of pericardial ﬂuid (7.34± 0.11), pyrazinamide peak concentrations
were ~40-times lower than the pH-adjusted MIC. Of the four drugs
tested, isoniazid was the only one to reach effective pericardial ﬂuid
concentrations. Likewise in TBM, the contribution of ethambutol during
treatment is questionable as ethambutol has poor CSF penetration
(Donald, 2010). Isoniazid and pyrazinamide are considered invaluable
during TBM treatment as both penetrate well into CSF (Donald, 2010).
However, adequate Cmax concentrations proposed for pyrazinamide in
TBM are based on ﬁndings of in vitro studies, healthy volunteers and pul-
monary TB and have not been informed by the pH of CSF during TBM.
Taken together, these ﬁndings support future trials to investigate
the utility of alternative drug regimens in patients with severe formsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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may contribute to poor outcome. There is increasing concern that the
conventionally prescribed dose of rifampicin (10 mg/kg/day) is too
low, both for treating pulmonary TB (van Ingen et al., 2011) and
extra-pulmonary TB (e.g. TBM) (Te Brake et al., 2015). Higher-than-
normal doses of rifampicin (up to 35 mg/kg/day), combined with the
other standard-of-care drugs given for 7 days, appear to be safe, result
in increased rifampicin exposure and associatewith a greater estimated
fall in bacillary load compared to doses of 10 mg/kg/day in pulmonary
TB patients (Boeree et al., 2015). Furthermore, in a TBM trial rifampicin,
administered intravenously at doses of ~13 mg/kg/day compared to
oral doses of ~10 mg/kg/day, resulted in higher rifampicin exposure
(as measured by plasma AUC0–6 h, plasma Cmax and the highest concen-
tration measured in CSF) which was, in turn, associated with increased
survival during the ﬁrst 2 weeks of TBM treatment (Te Brake et al.,
2015). Mortality was not the primary outcome and the sample size
was small (n= 60), but these results emphasize the need for bigger tri-
als to assess the utility of higher doses of rifampicin given intravenously,
in frequently lethal forms of TB. It further seems logical to consider
alternative drugs with good drug penetration into the disease site (e.g.
ﬂuoroquinolones such as moxiﬂoxacin and levoﬂoxacin that show
good penetration into CSF during TBM), for treating severe forms of
TB. However, a recent study that investigated the spatial distribution
of TB drugs in intact biopsied lung lesions from TB patients using a
matrix-assisted laser desorption/ionization (MALDI) mass spectrome-
try suite reveals a caveat of such an approach (Prideaux et al., 2015).
This study found that moxiﬂoxacin, although present at higher concen-
trations in lesions (as measured in homogenized lesions) than in
plasma, was inhomogeneously distributed within the lesions with
poor penetration into acellular caseum where bacilli may reside.
Although the study by Shenje and colleagues (Shenje et al., 2015) will
undoubtedly advance knowledge in theﬁeld of TBdrug PK/PD consider-
ably, it is important to consider that drug concentrations in accessible
ﬂuid adjacent to primary disease sites, i.e. pericardial ﬂuid, and CSF,
may provide an incomplete picture of drug concentrations within af-
fected tissue, i.e. pericardiumandmeninges, respectively. Optimistically
we consider that technologies such as the MALDI mass spectrometrysuite will be developed to assess TB drug distribution in tissues in vivo
which will provide the next piece in the puzzle of TB drug PK/PD in all
forms of TB.
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